WELCOME TO

PANONCOLOGY REFERRAL NETWORK

www.panoncologytrials.com

October, 2026

BREAST CANCER AWARENESS MONTH

PanOncology Spotlight: 3 Breast Cancer Trials Now Open

This October, we're bringing new options to the patients you already follow with advanced breast cancer. Three studies are now enrolling at PanOncology sites, spanning first-line HR+/HER2- disease, HER2-expressing disease after T-DXd, and tumors with PI3K pathway alterations.

FIRST LINE · HR+/HER2- · PIK3CA-MUTATED

Inavolisib + CDK4/6 inhibitor + letrozole

Endocrine-sensitive advanced disease · Phase III

Bayamón, Cayey, Ciudadela, Dorado, Hospital Oncológico, Manatí, Mayagüez, Ponce · NCT06790693

SECOND LINE+ · HER2-EXPRESSING · POST-T-DXd

Disitamab vedotin

HER2+, HER2-low or HER2-ultralow after prior therapy · Phase 1b/2

Hospital Oncológico · NCT06966453

SECOND LINE · HR+/HER2- · AKT/PI3K/PTEN-ALTERED

TER-2013 + fulvestrant

After an aromatase inhibitor–containing regimen · Phase 1/2

Hospital Oncológico · NCT07109726

💡 **Test early:** BRCA, PIK3CA and AKT/PTEN results decide who qualifies for these trials. A key takeaway from our October 3 Hereditary Cancer Syndromes Symposium.

Check the Complete Newsletter Here